Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

PURPOSE: Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setti...

Full description

Bibliographic Details
Main Authors: Midgley, R, McConkey, C, Johnstone, E, Dunn, J, Smith, J, Grumett, SA, Julier, P, Iveson, C, Yanagisawa, Y, Warren, B, Langman, M, Kerr, D
Format: Journal article
Language:English
Published: 2010

Similar Items

Similar Items